Bakris G, Oshima M, Mahaffey KW, et al. - Given that canagliflozin [sodium glucose cotransporter 2 inhibitor] decreased the risk of kidney failure as well as cardiovascular events in patients with type 2 diabetes mellitus and CKD in the CREDENCE trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation), researchers undertook this post hoc analysis to assess participants with eGFR < 30 ml/min per 1.73 m² at randomization. Employing a piecewise, linear, mixed-effects model, impacts of eGFR slope through week 130 were assessed. Experts found a 66% difference in the mean rate of eGFR reduction with canagliflozin vs placebo, from weeks 3 to 130. Findings of this post hoc analysis revealed that progression of kidney disease was slowed down by canagliflozin, without increasing AKI, even in patients with eGFR <30 ml/min per 1.73 m².